Tesamorelin trial data – does it really cut visceral fat for non‑HIV users?

Posted by fasted_scientist in GH & Growth Peptides - 1 points, 0 comments.

https://peptideslabuk.com/tesamorelin-uk-complete-research-guide-2026

This is an NCBI clinical review report that pulls together the Phase 3 LIPO‑010 and LIPO‑011 studies of tesamorelin in HIV‑positive adults with antiretroviral‑related lipodystrophy. It highlights the 8‑16% reduction in visceral adipose tissue after 26 weeks and the accompanying IGF‑1 rises.

For me the numbers look solid but the cohort is very specific – HIV patients on ART with already elevated visceral fat. I’ve never seen that kind of fat loss with ipamorelin or MK‑677 in healthy guys; my own experience is more about sleep quality and modest recovery tweaks. I wonder if the mechanism is mainly driven by the abnormal metabolic milieu in those patients rather than a pure GH effect.

Has anyone here tried tesamorelin off‑label for body composition and actually measured a comparable VAT drop, or does it seem more like a placebo effect outside the HIV context? Also, what dosing have you found hits saturation without excessive IGF‑1 spikes?

Community discussion - research and educational context only. Not medical advice.